Table 2.
Outcomes during follow-up.
| Event | N (%) |
|---|---|
| Nonaccidental death | 47 (23.5) |
| MACE | 48 (24) |
| Myocardial infarction | 35 (17.5) |
| Stroke | 13 (6.5) |
| NADM | 105 (52.5) |
| Anus | 19 (9.5) |
| Hodgkin's lymphoma | 12 (6) |
| Skin (non-melanoma) | 10 (5) |
| Lung | 8 (4) |
| Liver | 7 (3.5) |
| Colorectal | 6 (3) |
| Non-specified metastasis | 6 (3) |
| Cervical | 5 (2.5) |
| Hematologic | 5 (2.5) |
| Prostate | 5 (2.5) |
| Soft tissue | 4 (2) |
| Head and neck | 4 (2) |
| Bladder | 3 (1.5) |
| Melanoma | 2 (1) |
| Uterus | 2 (1) |
| Breast | 1 (0.5) |
| Brain | 1 (0.5) |
| Pancreas | 1 (0.5) |
| Penis | 1 (0.5) |
| Stomach | 1 (0.5) |
| Testicle | 1 (0.5) |
| Vulva | 1 (0.5) |
Abbreviations: MACE, major adverse cardiovascular event; NADM, non-AIDS-defining malignancy.